ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen (patented nicotinamide riboside, or NR) in various health outcomes.
- ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen (patented nicotinamide riboside, or NR) in various health outcomes.
- Through the industry-leading ChromaDex External Research Program (CERP), ChromaDex supplies Niagen to researchers around the world at no cost to help advance the understanding of NRs impact on various age-related health conditions.
- Overall, these findings provide important insights into the interconnection between NR, cellular senescence, and neuroinflammation in AD and warrant further investigation.
- The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.